INmune Bio (INMB) announced the publication of a seminal paper in the journal Cell Reports that demonstrates XPro1595 promotes remyelination in an animal model of demyelinating disease. The study was performed under the direction of Leslie Probert, head of immunology at the Hellenic Pasteur Institute in Athens Greece, and is the culmination of several years of work supported by EU research grants. Myelin is necessary for fast and efficient communication between neurons. Loss of myelin compromises neuron function and communication and is a step in the neurodegenerative process of many CNS diseases, including Alzheimer’s Disease.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INMB:
- INmune Bio initiated with a Buy at Alliance Global Partners
- INmune Bio completes enrollment for Phase 2 trial in Early AD
- INmune Bio initiated with an Outperform at Raymond James
- INmune announces initial results from Phase I/II trial of INKmune with mCRPC
- INmune Bio announces results of additional interim analysis of Phase 2 trial